Khavinson Peptides and Bioregulators: A Complete Guide

Key Takeaways

• Compounds covered: Epithalamin, Epithalon (Epitalon; AEDG), thymalin, cortexin, retinalamin, and the bioregulator class broadly
• Goal area: Longevity, aging biology, proposed organ-specific regulatory peptide modulation
• Evidence range: Strongest evidence: 6-to-8-year human clinical program with mortality data (non-blinded). Supporting evidence: animal lifespan extension studies; in vitro telomere and epigenetic mechanistic data; clinical program data for individual bioregulators in Russian medical practice.
• Regulatory range: None are FDA-approved for longevity use. As of April 22, 2026, Epitalon was removed from the FDA Category 2 bulk substances list pending renewed PCAC review (July 2026 / February 2027); no Khavinson compound currently has a clear Category 1 or Category 2 pathway. The biological extracts (epithalamin, thymalin, cortexin, retinalamin) do not meet 503A bulk sourcing requirements (no FDA-approved drug component, no USP/NF monograph, not on the bulk substances list) and are not compoundable under 503A in the ordinary course.
• Key biomarkers: IGF-1, hs-CRP, CBC, thyroid panel, comprehensive metabolic panel, HbA1c
• As of April 22, 2026: No Khavinson bioregulator has received FDA approval for any indication. Epitalon was removed from the FDA Category 2 bulk substances list on April 22, 2026 pending renewed PCAC review. The strongest available human longevity evidence in this category is the Khavinson 2003 mortality study — non-blinded, Russian clinical program data, not an FDA-reviewed randomized controlled trial.
• Bottom line: The bioregulator concept is scientifically serious and the human data are among the most developed in non-approved longevity peptide research. They are not, however, equivalent to Phase III randomized controlled trial evidence.

Understanding Peptide Bioregulation: The Biology

The bioregulator concept rests on a specific biological hypothesis: that organ function is regulated in part by short peptides produced locally within each tissue, and that the age-related decline of these peptides contributes materially to tissue dysfunction and systemic aging. Khavinson's 2002 review in Neuroendocrinology Letters proposed the peptide theory of aging — arguing that organ-specific regulatory peptides function as information carriers that coordinate gene expression within target tissues, and that their decline with age creates a measurable regulatory deficit.

This framework aligns with the broader Hallmarks of Aging established by López-Otín and colleagues, whose 2023 Cell update described epigenetic alterations, loss of proteostasis, and intercellular communication disruption as canonical aging mechanisms. Bioregulators are proposed to modulate the epigenetic alteration and intercellular communication hallmarks specifically — engaging gene expression signals that organs use to maintain their specialized functions.

Khavinson and colleagues, in Advances in Gerontology in 2002, described the tissue-specificity principle for organ peptides: peptides from a given organ show preferential activity in culture from tissue of the same type and age. This organ-specificity is what distinguishes bioregulators from systemic peptide hormones. Each bioregulator is, in the Khavinson framework, proposed to engage the local signaling environment that the target organ uses for normal function — not a systemic intervention.

Anisimov and colleagues, reviewing peptide bioregulation of aging in Biogerontology in 2010, summarized evidence for 20 to 40% lifespan extension in rodents across the bioregulator class, providing the preclinical breadth that complements the human clinical program data.

The Khavinson Bioregulators: A Quick Comparison

The following bioregulators are among the most studied in Khavinson's research program. They are listed by the depth of available human evidence, strongest first.

• Compound: Thymalin + epithalamin (combined clinical program — these compounds were administered together in Khavinson's long-term mortality study and the mortality data applies to the combination, not to either compound individually)
  Mechanism: Thymalin: proposed thymic immune modulation; epithalamin: proposed pineal signaling / melatonin rhythm modulation; combined: multi-system effects proposed in the bioregulator framework
  Evidence: 6-to-8-year non-blinded human clinical program, N=266 elderly subjects, 2-to-4-fold lower mortality vs. standard-care controls; 20–40% animal lifespan extension in rodent studies
  FDA status: Not FDA-approved. These biological extracts do not satisfy any of the three § 353a(b)(1)(A)(i) bulk-sourcing pathways (no FDA-approved drug component, no USP/NF monograph, not on the FDA bulk substances list); they are not compoundable under 503A in the ordinary course, and 503B outsourcing facility compounding is unavailable.
  SP availability: Not available through Superpower
• Compound: Epithalon (Epitalon; AEDG synthetic tetrapeptide)
  Mechanism: Telomerase activation; telomere elongation; epigenetic gene expression regulation; pineal-melatonin signaling
  Evidence: In vitro telomerase/telomere studies; animal lifespan extension; human circadian melatonin study; independent in vitro replication of telomere effect (2025)
  FDA status: Not FDA-approved. Removed from FDA Category 2 bulk substance list on April 22, 2026, pending PCAC re-review (July 2026 / Feb 2027); 503A compounding access is currently constrained pending that review
  SP availability: Not available through Superpower
• Compound: Cortexin
  Mechanism: Proposed neuroprotection; neuronal survival support; anti-excitotoxic and anti-oxidant effects in CNS
  Evidence: Russian clinical program data for ischemic stroke and cognitive dysfunction; limited English-language peer-reviewed trials
  FDA status: Not FDA-approved. Bovine cerebral cortex extract is not on the FDA bulk drug substances list, does not have a USP/NF monograph, and is not a component of any FDA-approved drug product; it is not compoundable under 503A in the ordinary course
  SP availability: Not available through Superpower
• Compound: Retinalamin
  Mechanism: Retinal tissue peptide activity; proposed to support retinal cell differentiation and protective functions
  Evidence: Laboratory differentiation studies; Russian clinical program data for retinal conditions
  FDA status: Not FDA-approved for any indication in the United States. Bovine retinal extract is not on the FDA bulk drug substances list, does not have a USP/NF monograph, and is not a component of any FDA-approved drug product; it is not compoundable under 503A in the ordinary course
  SP availability: Not available through Superpower

Individual Bioregulator Profiles

Each bioregulator addresses a different organ system and has a different evidence base. They share the common framework of tissue specificity and proposed regulatory peptide modulation but are not interchangeable.

Epithalamin and Epithalon: pineal gland and longevity

Epithalamin is the original pineal gland extract from Khavinson's program; Epithalon (AEDG) is its synthetic tetrapeptide analog. The two are discussed together because the human clinical program used epithalamin while most mechanistic research has since focused on the synthetic Epithalon.

Khavinson's foundational 2003 mortality study, published in Neuroendocrinology Letters, described a 6-to-8-year clinical follow-up of 266 elderly subjects receiving thymalin and epithalamin versus standard care controls. Combined-treatment subjects (non-blinded, uncontrolled for randomization) experienced mortality rates 2 to 4-fold lower than standard-geriatric-care controls over the observation period. The companion 2002 Advances in Gerontology analysis by Khavinson and colleagues reported mortality 4.1-fold lower in the combined-treatment group than in controls. These findings are from a non-blinded clinical program, not a double-blind placebo-controlled trial — but they represent some of the longest-running human longevity follow-up data for any peptide in this category.

The mechanistic basis for Epithalon's longevity effects has been developed through Khavinson's in vitro and cell-line work. Khavinson and colleagues, in the Bulletin of Experimental Biology and Medicine in 2003, demonstrated that Epithalon induces telomerase activity and telomere elongation in telomerase-negative human somatic cells. A 2004 companion study showed Epithalon enabled fibroblasts to exceed the Hayflick limit. Al-Dulaimi and colleagues, in Biogerontology in 2025, provided independent replication of telomere effect via telomerase upregulation or ALT activity — the most significant independent replication of Khavinson's mechanistic claims.

Khavinson and colleagues, in Molecules in 2020, described AEDG stimulation of gene expression during neurogenesis via a possible epigenetic mechanism, suggesting that Epithalon's effects extend into neurological aging beyond telomere biology. Anisimov and colleagues, in Biogerontology in 2003, showed Epitalon extended lifespan in SHR mice and reduced spontaneous tumor incidence. Korkushko and colleagues, writing in the Bulletin of Experimental Biology and Medicine in 2004, demonstrated that epithalamin improved circadian melatonin rhythm in elderly subjects — a human study showing a specific measurable effect of the biological extract, consistent with the pineal-signaling hypothesis.

Evidence level: In vitro telomere studies; animal lifespan extension; human observational clinical program; human circadian melatonin study.

Thymalin: proposed thymic immune modulation

Thymalin is a multi-peptide thymic extract developed as the immune-system bioregulator in Khavinson's program. Its target is the thymus, an organ central to T-cell maturation that undergoes significant involution with age. Thymic involution is well-established as a driver of immunosenescence.

A 2020 paper in Immunity & Ageing by Thomas and colleagues reviewed contributions of thymic involution to immunosenescence, establishing that thymic decline is a primary mechanism of age-related immune dysfunction. A 2010 paper in Aging (Albany NY) by Appay and colleagues reviewed the role of the thymus in immunosenescence, drawing on data from thymectomized individuals to establish how much of normal immune aging is thymus-dependent. These papers establish the biological problem that thymalin aims to address.

A 2020 paper in the Bulletin of Experimental Biology and Medicine by Khavinson and colleagues described thymalin's activation of human hematopoietic stem cell differentiation — providing mechanistic data on how the peptide acts on hematopoietic stem cell development. A 2014 paper in Current Pharmaceutical Design by Reggiani and colleagues reviewed the physiology and therapeutic potential of thymulin, a related thymic peptide that provides context for thymalin within the broader class of thymic compounds including thymosin alpha-1, thymulin, and related peptides.

Khavinson and colleagues, in Advances in Gerontology in 2013, clinical studies across the bioregulator panel, presenting multi-year data from the Russian clinical program spanning conditions from cardiovascular disease to immune function. The combined thymalin–epithalamin mortality data from the Khavinson 2003 mortality study described above applies here: thymalin was one of the two compounds in the combined treatment arm.

Evidence level: Animal studies; Russian clinical program data; human mechanistic cell-line data; combined program mortality data.

Cortexin: proposed cerebral cortex neuroprotection

Cortexin is a polypeptide bioregulator derived from bovine cerebral cortex, used in Russian clinical medicine for ischemic stroke, traumatic brain injury, and cognitive disorders. It is among the most widely prescribed neuroprotective agents in Russian medical practice, used intravenously or intramuscularly in acute neurological conditions.

A 2015 paper in Zhurnal Nevrologii i Psikhiatrii (the Russian Journal of Neurology and Psychiatry) described cortexin's molecular mechanisms and neurological targets, covering anti-excitotoxic, antioxidant, and neurotrophin-modulating properties. A multicenter study on cortexin in pediatric cognitive dysfunction, published in the same journal in 2018, reported improvements in pediatric cognitive metrics. The pediatric evidence framing should be noted: this is not an adult longevity study.

A 2013 paper in Advances in Gerontology by Umnov and colleagues reviewed neuroprotective effects of peptide bioregulators in people of various ages, covering cortexin alongside other CNS bioregulators and presenting Russian clinical program data for the class.

The evidence base for cortexin relies heavily on Russian-language publications from clinical programs that do not meet Western RCT standards. This is a consistent limitation across the cortexin literature and should inform how confidence is calibrated when evaluating claims about this compound. Cortexin is not FDA-approved and has very limited US clinical availability.

Evidence level: Russian clinical program data; limited peer-reviewed English-language RCT evidence; not an FDA-recognized clinical evidence base.

Retinalamin: retinal tissue bioregulation

Retinalamin is a polypeptide bioregulator derived from bovine retinal tissue. It has been used in Russian ophthalmological clinical practice for retinal dystrophies and glaucoma, based on Russian-language clinical program data that does not meet Western RCT standards; it is not FDA-approved for any indication. A 2002 paper in the Bulletin of Experimental Biology and Medicine by Khavinson and colleagues described retinal peptide inductive activity on retinal tissue differentiation, providing the mechanistic basis for retinalamin's proposed organ-specific activity.

Khavinson and colleagues, in the 2013 Advances in Gerontology clinical review, included retinalamin in the clinical results survey alongside the other major bioregulators. As with cortexin, the evidence base is predominantly Russian clinical program data with limited peer-reviewed English-language trial data. Retinalamin is not FDA-approved and is not available through US clinical channels for longevity applications.

Evidence level: Russian clinical program data; mechanistic laboratory studies; not FDA-reviewed evidence.

The Peptide Theory of Aging: Scientific Context

Khavinson's peptide theory of aging — that declining regulatory peptide synthesis in key organs is a primary driver of aging — is a specific hypothesis within the broader aging science literature. It is not the same claim as the Hallmarks of Aging framework, though it overlaps with the intercellular communication disruption and epigenetic alteration hallmarks. The peptide theory has not been subjected to the same independent international replication program as other aging biology frameworks, and the evidence for specific bioregulator mechanisms is substantially concentrated in Khavinson's own laboratory and clinical program.

The strongest independently derived evidence for the telomere mechanism — the Al-Dulaimi 2025 Biogerontology study confirming Epithalon's telomere elongation effect — is meaningful precisely because it comes from outside Khavinson's group. The more a specific mechanism claim has been independently replicated, the stronger the scientific confidence level. For Epithalon's telomere effect, independent replication exists. For the mortality claims from the clinical program, the methodology does not permit independent randomized replication by definition.

A 2012 paper in Advances in Gerontology by Khavinson and colleagues surveyed experimental evidence across the bioregulator class and a 2013 companion paper reviewed clinical results for the major compounds — together representing the most comprehensive English-accessible review of the full Khavinson evidence base. A 2009 paper in Vopr Onkol (Questions of Oncology) described 35 years of cancer-incidence observations in the bioregulator program, framed explicitly as preclinical and observational findings rather than clinical trial evidence.

An early 2000 review by Khavinson in Klinicheskaia Meditsina summarized the first generation of clinical use of peptide bioregulators in gerontology, providing historical context for how the program developed over time.

Regulatory Status at a Glance

As of April 22, 2026, the Khavinson bioregulators carry the following regulatory statuses in the United States.

• Epithalon (Epitalon; AEDG tetrapeptide): Not FDA-approved for any indication. Was on the FDA Pharmacy Compounding Advisory Committee (PCAC) Category 2 bulk drug substances list under enforcement discretion, and was removed from Category 2 on April 22, 2026 (one of 12 peptides removed) pending renewed PCAC review scheduled for July 2026 and February 2027. Removal from Category 2 is not equivalent to Category 1 positive-list inclusion; Epitalon does not satisfy any of the three statutory bulk-sourcing pathways at 21 U.S.C. § 353a(b)(1)(A)(i) (no FDA-approved drug component, no USP/NF monograph, not on the Category 1 list), so 503A compounding from bulk substance is not within FDA's compliance framework during the PCAC review period. 503B outsourcing facility compounding is likewise unavailable. Not available through Superpower.
• Epithalamin (pineal extract): Not FDA-approved. Not a component of any FDA-approved drug, does not have a USP/NF monograph, and is not on the FDA bulk drug substances list under 21 U.S.C. § 353a(b)(1)(A) — not compoundable under 503A in the ordinary course. 503B compounding also unavailable. Not available through Superpower.
• Thymalin (thymic extract): Not FDA-approved. Not a component of any FDA-approved drug, does not have a USP/NF monograph, and is not on the FDA bulk drug substances list — not compoundable under 503A in the ordinary course. 503B compounding also unavailable. Not available through Superpower.
• Cortexin (cerebral cortex extract): Not FDA-approved. Not a component of any FDA-approved drug, does not have a USP/NF monograph, and is not on the FDA bulk drug substances list — not compoundable under 503A in the ordinary course. 503B compounding also unavailable. Not available through Superpower.
• Retinalamin (retinal extract): Not FDA-approved. Not a component of any FDA-approved drug, does not have a USP/NF monograph, and is not on the FDA bulk drug substances list — not compoundable under 503A in the ordinary course. 503B compounding also unavailable. Not available through Superpower.

Considerations When Evaluating Khavinson Bioregulators

Evaluating the Khavinson bioregulators fairly requires holding two distinct things simultaneously: the evidence base is the most developed for any non-approved peptide longevity compound, and the evidence base does not meet the standard of Western randomized controlled trial methodology. Both of these are true. Neither cancels the other.

Interpreting non-blinded clinical program data: The observed lower-mortality data from the Khavinson program is clinically striking. However, non-blinded studies in elderly populations are susceptible to significant confounders: differences in healthcare access between treatment and control groups, selection bias in who received treatment, Hawthorne effects from clinical program participation, and the absence of pre-specified primary endpoints. These are not reasons to dismiss the findings; they are reasons to hold confidence at an appropriate level until randomized replication exists.

Independence of evidence: Much of the Khavinson bioregulator evidence originates from Khavinson's own research program. The 2025 Al-Dulaimi independent replication of Epithalon's telomere effect is significant partly because it demonstrates that the mechanism is not confined to a single laboratory's data. For the clinical program data, no independent replication of the 6-to-8-year mortality study exists.

Compound selection by organ target: A provider evaluating bioregulator options would be guided by the organ system with the most clinical relevance to the individual patient. Thymalin's proposed thymic immune mechanism is of research interest in the context of documented immunosenescence markers. Epithalon's proposed telomere and epigenetic mechanisms are of research interest in the cellular and metabolic aging domain. Cortexin's proposed neuroprotective applications require a neurological clinical context. Any clinical conversation remains governed by the absence of RCT evidence and the current 503A regulatory posture described above.

Access pathway: Among the Khavinson compounds, Epitalon (the synthetic tetrapeptide) previously had the most defined US compounding posture — it was on the FDA Category 2 bulk substances list under enforcement discretion — but was removed from Category 2 on April 22, 2026 pending PCAC re-review. The biological extract formulations (epithalamin, thymalin, cortexin, retinalamin) have never been on the FDA bulk substances list, do not have USP/NF monographs, and are not components of any FDA-approved drug product; they are not compoundable under 503A in the ordinary course. Any clinical use requires a provider evaluation and prescription, and readers should verify current FDA regulatory status before any such discussion.

A licensed provider will evaluate your full health history, current medications, and baseline laboratory results before recommending any compound in this category.

Safety Considerations

The Khavinson bioregulator program has operated over decades with an observable safety record in Russian clinical use. Serious adverse events have not been prominently reported in the published literature for the major compounds. However, the absence of documented serious adverse events in a non-blinded clinical program is not equivalent to the safety characterization from a controlled Phase 1 trial with systematic adverse event collection.

Peptide bioregulators are generally low-molecular-weight compounds with short half-lives; the theoretical concern profile for small peptides is lower than for larger biologics. However, no long-term Western pharmacovigilance data exist for these compounds.

Contraindications that apply broadly to Khavinson bioregulator therapy include:

• Active or history of malignancy — compounds with effects on telomerase activity (Epithalon), T-cell regulation (thymalin), or cell proliferation carry theoretical concerns requiring clinician evaluation; the anti-tumor signals from Khavinson's oncology observational program are preclinical and observational and should not be taken as clinical cancer protection
• Pregnancy — no reproductive safety data in Western-standard trials exist for these compounds
• Active autoimmune disease receiving immunosuppression — thymalin's immunostimulatory effects may interact with immunosuppressive treatment regimens
• Use of unverified sources — products obtained outside licensed compounding channels carry contamination and potency risks

For compound-specific safety context, consult the available published literature and discuss with a licensed provider familiar with this compound class.

What to Test Before Exploring Khavinson Bioregulators

Baseline biomarker testing establishes the objective reference point needed to assess whether any compound is producing the expected physiological changes. This is particularly important for compounds where the clinical evidence comes from observational programs rather than controlled trials with pre-specified biological endpoints.

• IGF-1: GH axis and tissue repair context. Relevant baseline for any longevity-oriented evaluation. A baseline IGF-1 level characterizes where the GH axis currently stands before any intervention.
• hs-CRP (high-sensitivity C-reactive protein): Systemic inflammatory aging indicator. hs-CRP testing characterizes the inflammaging burden against which any anti-inflammatory or immunomodulatory peptide effect can be measured.
• CBC and immune differential: Characterizes the current immune cell profile, including lymphocyte populations relevant to thymalin's proposed mechanism of T-cell support.
• Thyroid panel (TSH, free T3): Thyroid dysfunction produces fatigue and cognitive symptoms that overlap with age-related decline and can confound any assessment of a longevity intervention's effects.
• HbA1c and fasting glucose: Metabolic aging trajectory markers. Relevant context for any longevity intervention evaluation.
• Comprehensive metabolic panel: Liver enzymes (ALT, AST) and kidney function (eGFR) establish organ function baseline and safety clearance for injectable compounds.

IGF-1, hs-CRP, CBC, thyroid function, and comprehensive metabolic panel together establish the biological baseline most relevant to Khavinson bioregulator evaluation. The cellular aging and longevity biomarker guide provides a detailed reference for interpreting these markers in a longevity context.

Access Status for These Compounds

The April 22, 2026 FDA action materially narrowed the US access picture for Epitalon (the synthetic AEDG tetrapeptide). Epitalon was on the PCAC Category 2 bulk drug substances list — the "under further review, subject to enforcement discretion" tier — until it was removed on April 22, 2026 pending renewed PCAC review scheduled for July 2026 and February 2027. Epitalon is not a component of any FDA-approved drug, does not have a USP/NF monograph, and is not on the Category 1 positive list — it therefore does not satisfy any of the three statutory bulk-sourcing pathways at 21 U.S.C. § 353a(b)(1)(A)(i), and 503A compounding of Epitalon as a bulk substance is not currently within FDA's compliance framework. 503B outsourcing facility compounding is similarly unavailable. The biological extract formulations — epithalamin, thymalin, cortexin, retinalamin — also do not satisfy any of the three § 353a(b)(1)(A)(i) pathways and are not compoundable under 503A in the ordinary course. Readers should verify current FDA status directly at FDA.gov before any clinical discussion.

Any clinical conversation about a Khavinson bioregulator should happen with a provider who understands the current FDA Category 1 / Category 2 review cycle and the April 22, 2026 action. A complete health history, medication review, baseline laboratory workup, and informed discussion of the available evidence base and its methodological limitations are prerequisites.

Products sold as Khavinson peptides through online vendors without a prescription are not subject to pharmaceutical manufacturing standards. For injectable compounds specifically, unverified online products carry contamination and dosing risks that cannot be mitigated by the end user.

Understanding Your Baseline

The Khavinson bioregulator program represents one of the most sustained long-term investments in peptide-based longevity research conducted in clinical settings. That it has not yet been subjected to Western randomized controlled trial methodology does not erase the substance of what Khavinson's group has documented; it does mean that the confidence level for specific efficacy claims is lower than it would be for a compound with Phase III RCT data. Both of those things are worth holding clearly.

What is not uncertain is that the biological processes these compounds aim to address — thymic involution, pineal melatonin decline, epigenetic drift, telomere attrition — are real, measurable, and associated with aging. Establishing your current position on those biological trajectories through biomarker testing gives any subsequent clinical conversation a factual foundation.

Superpower does not offer, compound, or distribute any Khavinson bioregulator. This content is provided as an educational synthesis of the published scientific literature; it is not a recommendation of use and does not constitute clinical advice.

That principle is central to Superpower's approach to preventive health: objective data about where your biology currently stands is the starting point for any health decision, including decisions about compounds with complex and nuanced evidence bases.

IMPORTANT SAFETY INFORMATION

Epithalon (Epitalon; AEDG tetrapeptide) is not FDA-approved for any indication in the United States. It is not a component of any FDA-approved drug product. As of April 22, 2026, Epitalon was removed from the FDA's Category 2 bulk drug substance list pending renewed PCAC review (July 2026 and February 2027). It is not currently available through a straightforward 503A compounding pathway; any US access is outside standard enforcement-discretion conditions and the compliance posture of any 503A pharmacy compounding it should be independently verified. 503B outsourcing facility compounding is not available. The longevity-relevant evidence consists primarily of in vitro studies, animal models, and Khavinson's non-blinded clinical program data — not FDA-reviewed randomized controlled trial evidence. Safety and efficacy for anti-aging or longevity indications have not been established through adequate and well-controlled clinical trials recognized by the FDA. Not available through Superpower.

Thymalin and epithalamin are biological extract formulations. They are not FDA-approved for any indication. They are not components of any FDA-approved drug, do not have USP/NF monographs, and are not on the FDA bulk drug substances list — they are not compoundable under 503A in the ordinary course, and 503B outsourcing facility compounding is also unavailable. The human longevity evidence is from a non-blinded Russian clinical program. Randomized controlled trial evidence for longevity endpoints is not available. Not available through Superpower.

Cortexin and retinalamin are polypeptide biological extracts not FDA-approved for any indication in the United States. They are not components of any FDA-approved drug, do not have USP/NF monographs, and are not on the FDA bulk drug substances list — they are not compoundable under 503A in the ordinary course, and 503B outsourcing facility compounding is also unavailable. Evidence is from Russian clinical programs; peer-reviewed English-language randomized controlled trial data are limited. Not available through Superpower for longevity or anti-aging applications.

All Khavinson bioregulators require a licensed provider evaluation and prescription for any clinical use. Products obtained through unregulated online channels carry contamination, potency, and identity risks inherent in the absence of pharmaceutical manufacturing oversight.

Full FDA-approved prescribing information at dailymed.nlm.nih.gov.

Disclaimer: This article discusses multiple peptide bioregulators not FDA-approved for any indication in the United States. Evidence is primarily from Khavinson's Russian clinical programs and animal studies; no FDA-reviewed randomized controlled trial data exist for longevity endpoints. Superpower does not facilitate access to these compounds. This educational content is editorially independent.